百克生物：2025年营收降51.85%，净利润由盈转亏

Core Viewpoint - The company reported a significant decline in revenue and net profit for the fiscal year 2025, primarily due to vaccine returns, price reductions, and decreased sales of varicella vaccines [1] Financial Performance - Total operating revenue for 2025 was 591.81 million yuan, a year-on-year decrease of 51.85% [1] - The net profit attributable to the parent company was -272.07 million yuan, reflecting a year-on-year decline of 217.22% [1] Asset and Equity Status - As of the end of the reporting period, total assets amounted to 506.15 million yuan, down 2.75% year-on-year [1] - The equity attributable to the parent company's shareholders was 384.15 million yuan, a decrease of 8.92% compared to the previous year [1] Strategic Initiatives - The company is advancing marketing initiatives and plans to accelerate the realization of results from its research and development pipeline [1]